Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.

Lancet (London, England)
2021
https://researcherprofiles.org/profile/212338669
34217393
Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P